Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.
BACKGROUND: Pediatric acute myeloid leukemia (AML) remains a challenging disease to treat even with intensified cytarabine-based chemotherapy. Histone deacetylases (HDACs) have been reported to be promising therapeutic targets for treating AML. However, HDAC family members that are involved in chemo...
Main Authors: | Xuelian Xu, Chengzhi Xie, Holly Edwards, Hui Zhou, Steven A Buck, Yubin Ge |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2011-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3040224?pdf=render |
Similar Items
-
Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
by: Juan Zhang, et al.
Published: (2021-09-01) -
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
by: Qing-Yu Xu, et al.
Published: (2020-03-01) -
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51.
by: Chengzhi Xie, et al.
Published: (2013-01-01) -
Inhibition of Autophagy Does Not Re-Sensitize Acute Myeloid Leukemia Cells Resistant to Cytarabine
by: Nienke Visser, et al.
Published: (2021-02-01) -
Efficacy of Flotetuzumab in Combination with Cytarabine in Patient-Derived Xenograft Models of Pediatric Acute Myeloid Leukemia
by: Sonali P. Barwe, et al.
Published: (2022-02-01)